Patents by Inventor Junxuan Lu

Junxuan Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20240050509
    Abstract: Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.
    Type: Application
    Filed: February 21, 2023
    Publication date: February 15, 2024
    Applicant: KUALITY HERBCEUTICS LLC
    Inventors: Chengguo Xing, Stephen Hecht, Junxuan Lu, Pramod Upadhyaya, Sharon Murphy, Pablo Leitzman, Sreekanth Narayanapillai, Silvia Balbo
  • KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20210228672
    Abstract: Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.
    Type: Application
    Filed: January 5, 2021
    Publication date: July 29, 2021
    Applicant: KUALITY HERBCEUTICS LLC
    Inventors: Chengguo Xing, Stephen Hecht, Junxuan Lu, Pramod Upadhyaya, Sharon Murphy, Pablo Leitzman, Sreekanth Narayanapillai, Silvia Balbo
  • Kava derived therapeutic compounds and methods of use thereof
    Patent number: 10918687
    Abstract: Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: February 16, 2021
    Assignee: Kuality Herbceutics LLC
    Inventors: Chengguo Xing, Stephen Hecht, Junxuan Lu, Pramod Upadhyaya, Sharon Murphy, Pablo Leitzman, Sreekanth Narayanapillai, Silvia Balbo
  • KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20200261529
    Abstract: Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.
    Type: Application
    Filed: January 23, 2020
    Publication date: August 20, 2020
    Applicant: KUALITY HERBCEUTICS LLC
    Inventors: Chengguo Xing, Stephen Hecht, Junxuan Lu, Pramod Upadhyaya, Sharon Murphy, Pablo Leitzman, Sreekanth Narayanapillai, Silvia Balbo
  • Kava derived therapeutic compounds and methods of use thereof
    Patent number: 10624943
    Abstract: Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: April 21, 2020
    Assignee: Kuality Herbceutics, LLC
    Inventors: Chengguo Xing, Stephen Hecht, Junxuan Lu, Pramod Upadhyaya, Sharon Murphy, Pablo Leitzman, Sreekanth Narayanapillai, Silvia Balbo
  • KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160279184
    Abstract: Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.
    Type: Application
    Filed: November 11, 2014
    Publication date: September 29, 2016
    Applicant: KUALITY HERBCEUTICS LLC
    Inventors: Chengguo Xing, Stephen Hecht, Junxuan Lu, Pramod Upadhyaya, Sharon Murphy, Pablo Leitzman, Sreekanth Narayanapillai, Silvia Balbo